Continuous glucose monitoring is a safe and useful method to measure blood glucose levels in the hospital, especially during the COVID-19 pandemic.
Continuous glucose monitoring improves glycemic control in adolescents and young adults with T1D and is beneficial for hypoglycemia in older adults with T1D.
The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes.
Use of continuous glucose monitoring significantly decreases rates of hypoglycemia among children and adolescents who attend diabetes camps.
Researchers analyzed diabetes mobile applications to evaluate patient self-management capabilities and the compliance of these apps with diabetes care guidelines.
In-hospital use of continuous glucose monitoring may offer improvements in glycemic control and reduced exposure to COVID-19 for healthcare professionals.
Experts provide recommendations for effective implementation of telehealth for diabetes care, with a focus on patient-to-clinic video encounters.
Changes to restrictions for telemedicine may have important implications for the management of adult and pediatric diabetes during the COVID-19 pandemic.
For patients with T2D, glycemic control is similar with use of regular human insulin and rapid-acting insulin when delivered with a wearable insulin delivery device, V-Go.
Real-world data support the benefit of using the Medtronic MiniMed 670G insulin pump system for glycemic control in type 1 diabetes.
Applying functional data analysis to continuous glucose monitoring data can assist in identifying differences in maternal glucose control during pregnancy, which might go unnoticed using standard metrics.